105 related articles for article (PubMed ID: 8429674)
1. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.
Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
Leuk Res; 1993 Jan; 17(1):1-8. PubMed ID: 8429674
[TBL] [Abstract][Full Text] [Related]
2. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.
Mohammad RM; Diwakaran H; Maki A; Emara MA; Pettit GR; Redman B; al-Katib A
Leuk Res; 1995 Sep; 19(9):667-73. PubMed ID: 7564478
[TBL] [Abstract][Full Text] [Related]
3. Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors.
Li Y; Mohammad RM; al-Katib A; Varterasian ML; Chen B
Leuk Res; 1997 May; 21(5):391-7. PubMed ID: 9225065
[TBL] [Abstract][Full Text] [Related]
4. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.
Maki A; Diwakaran H; Redman B; al-Asfar S; Pettit GR; Mohammad RM; al-Katib A
Anticancer Drugs; 1995 Jun; 6(3):392-7. PubMed ID: 7670136
[TBL] [Abstract][Full Text] [Related]
5. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
Al-Katib AM; Smith MR; Kamanda WS; Pettit GR; Hamdan M; Mohamed AN; Chelladurai B; Mohammad RM
Clin Cancer Res; 1998 May; 4(5):1305-14. PubMed ID: 9607591
[TBL] [Abstract][Full Text] [Related]
6. Bryostatin 1 induces ubiquitin COOH-terminal hydrolase in acute lymphoblastic leukemia cells.
Mohammad RM; Maki A; Pettit GR; al-Katib AM
Enzyme Protein; 1996; 49(5-6):262-72. PubMed ID: 9252784
[TBL] [Abstract][Full Text] [Related]
7. Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model.
Mohammad RM; Adsay NV; Philip PA; Pettit GR; Vaitkevicius VK; Sarkar FH
Anticancer Drugs; 2001 Oct; 12(9):735-40. PubMed ID: 11593055
[TBL] [Abstract][Full Text] [Related]
8. Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh.
al-Katib A; Mohammad RM; Khan K; Dan ME; Pettit GR; Sensenbrenner LL
J Immunother Emphasis Tumor Immunol; 1993 Jul; 14(1):33-42. PubMed ID: 8399068
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.
al-Katib A; Mohammad RM; Dan M; Hussein ME; Akhtar A; Pettit GR; Sensenbrenner LL
Exp Hematol; 1993 Jan; 21(1):61-5. PubMed ID: 8093352
[TBL] [Abstract][Full Text] [Related]
10. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
Steube KG; Drexler HG
Leuk Lymphoma; 1993 Jan; 9(1-2):141-8. PubMed ID: 8477194
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437
[TBL] [Abstract][Full Text] [Related]
12. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).
Vrana JA; Saunders AM; Chellappan SP; Grant S
Differentiation; 1998 May; 63(1):33-42. PubMed ID: 9615391
[TBL] [Abstract][Full Text] [Related]
13. Varied differentiation responses of human leukemias to bryostatin 1.
Kraft AS; William F; Pettit GR; Lilly MB
Cancer Res; 1989 Mar; 49(5):1287-93. PubMed ID: 2917358
[TBL] [Abstract][Full Text] [Related]
14. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
16. Differentiating agents do not induce a true hairy cell phenotype in B-CLL cells in vitro.
Gartenhaus R; Hoffman M; Fuchs A; Billet H; Wang P; Gentile P; Rai K
Leuk Lymphoma; 1996 Jun; 22(1-2):97-101, follow.186, color plate IX. PubMed ID: 8724534
[TBL] [Abstract][Full Text] [Related]
17. Induced expression of alpha-enolase in differentiated diffuse large cell lymphoma.
Mohammad RM; Hamdan MY; al-Katib A
Enzyme Protein; 1994-1995; 48(1):37-44. PubMed ID: 7787969
[TBL] [Abstract][Full Text] [Related]
18. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.
Jones RJ; Sharkis SJ; Miller CB; Rowinsky EK; Burke PJ; May WS
Blood; 1990 Mar; 75(6):1319-23. PubMed ID: 2310830
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
Wall NR; Mohammad RM; Reddy KB; Al-Katib AM
Int J Mol Med; 2000 Feb; 5(2):165-71. PubMed ID: 10639596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
